

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/031,143	01/13/2002	Kenneth G. Mandel	C75101	8659
20462 7:	590 05/21/2002	OD ATION		
SMITHKLINE BEECHAM CORPORATION			EXAMINER	
CORPORATE INTELLECTUAL PROPERTY-US, UW2220 P. O. BOX 1539		JIANG, SHAOJIA A		
KING OF PRU	KING OF PRUSSIA, PA 19406-0939		ART UNIT	PAPER NUMBER
			1617	
			DATE MAILED: 05/21/2002	>

Please find below and/or attached an Office communication concerning this application or proceeding.

		<u></u>
•	Application No.	Applicant(s)
	10/031,143	MANDEL ET AL.
Office Action Summary	Examiner	Art Unit
	Shaojia A. Jiang	1617
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet w	ith the correspondence address
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a rep If NO period for reply is specified above, the maximum statutory period Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailir earned patent term adjustment. See 37 CFR 1.704(b). Status	136(a). In no event, however, may a bly within the statutory minimum of thir will apply and will expire SIX (6) MON te, cause the application to become Al	reply be timely filed ty (30) days will be considered timely. ITHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).
1) Responsive to communication(s) filed on		
	— his action is non-final.	
3) Since this application is in condition for allow closed in accordance with the practice under		
Disposition of Claims		
4) Claim(s) 1-12 is/are pending in the applicatio		
4a) Of the above claim(s) is/are withdra	awn from consideration.	
5) Claim(s) is/are allowed.		
6)⊠ Claim(s) <u>1-12</u> is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claim(s) are subject to restriction and/of Application Papers	or election requirement.	
9) The specification is objected to by the Examine	er	
10)☐ The drawing(s) filed on is/are: a)☐ acce		he Examiner
Applicant may not request that any objection to the	•	
11) The proposed drawing correction filed on		• •
If approved, corrected drawings are required in re		
12) The oath or declaration is objected to by the Ex	xaminer.	
Priority under 35 U.S.C. §§ 119 and 120		
13) Acknowledgment is made of a claim for foreig	n priority under 35 U.S.C.	§ 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:		
1. Certified copies of the priority documen	ts have been received.	
2. Certified copies of the priority documen	ts have been received in A	pplication No
 3. Copies of the certified copies of the pricapplication from the International But See the attached detailed Office action for a list 	ureau (PCT Rule 17.2(a)).	_
14) Acknowledgment is made of a claim for domest	•	
a) ☐ The translation of the foreign language pro	ovisional application has b	een received.
Attachment(s)	, , ===================================	
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 2	5) Notice of	Summary (PTO-413) Paper No(s) nformal Patent Application (PTO-152)
Patent and Trademark Office		

U.S. Patent and Trademark Office PTO-326 (Rev. 04-01) Application/Control Number: 10/031,143

Art Unit: 1617

DETAILED ACTION

This application is a 371 of PCT/US00/18896 which claims priority to provisional application Serial No. 60/143407.

Abstract

This application does not contain an abstract of the disclosure as required by 37 CFR 1.72(b). An abstract on a separate sheet is required.

Applicant is reminded of the proper language and format for an abstract of the disclosure.

The abstract should be in narrative form and generally limited to a single paragraph on a separate sheet within the range of 50 to 250 words. It is important that the abstract not exceed 250 words in length since the space provided for the abstract on the computer tape used by the printer is limited. The form and legal phraseology often used in patent claims, such as "means" and "said," should be avoided. The abstract should describe the disclosure sufficiently to assist readers in deciding whether there is a need for consulting the full patent text for details.

The language should be clear and concise and should not repeat information given in the title. It should avoid using phrases which can be implied, such as, "The disclosure concerns," "The disclosure defined by this invention," "The disclosure describes," etc.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 7 contains the trademark/trade name ANC. Where a trademark or trade name is used in a claim as a limitation to identify or describe a particular material or product, the claim does not comply with the requirements of 35 U.S.C. 112, second paragraph. See *Ex parte Simpson*, 218 USPQ 1020 (Bd. App. 1982). The claim scope

Art Unit: 1617

is uncertain since the trademark or trade name cannot be used properly to identify any particular material or product. A trademark or trade name is used to identify a source of goods, and not the goods themselves. Thus, a trademark or trade name does not identify or describe the goods associated with the trademark or trade name. In the present case, the trademark/trade name is used to identify/describe particular agent herein and, accordingly, the identification/description is indefinite.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-12 are rejected under 35 U.S.C. 103(a) as being unpatentable over Phillips (5,840,737, PTO-1449 submitted January 3, 2002).

Phillips discloses a method for treating gastric acid disorders including GERD(or heartburn) by administering to a human patient a pharmaceutical composition comprising an effective amount of omeprazole, a proton pump inhibitor, and sodium bicarbonate. See abstract, col.1 lines 27-29, col.12 line 38, and claims 1-3. Phillips also teaches that the amount of omeprazole to be administered with water is within the

Art Unit: 1617

instant claims and one of the dosage forms is solid compressed capsule. See col.12 lines 5-7 and lines 41-42, claim 12, and col.1 line 25.

Phillips does not expressly discloses a method of treating or preventing heartburn symptoms particularly, in a human.

It would have been obvious to a person of ordinary skill in the art at the time the invention was made to employ Phillips' composition in a method of treating or preventing heartburn symptoms in a human.

One having ordinary skill in the art would have been motivated to employ Phillips' composition in a method of treating or preventing heartburn symptoms in a human since heartburn is well known to be one of major symptoms of gastric acid disorders.

Therefore, Phillips' composition would have been reasonably expected to benefit the treatment of heartburn in a human. Further, Phillips teaches that the composition is expected to be useful in the treatment of heartburn as well as other gastric acid disorders.

Thus the claimed invention as a whole is clearly prima facie obvious over the combined teachings of the prior art.

In view of the rejections to the pending claims set forth above, no claims are allowed.

Application/Control Number: 10/031,143

Art Unit: 1617

Page 5

Any inquiry concerning this communication or earlier communications from the examiner should be directed to S. A. Jiang, whose telephone number is (703) 305-1008.

The examiner can normally be reached on Monday-Friday from 9:00 to 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Minna Moezie, J.D., can be reached on (703) 308-4612. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 305-1235.

Shaojia A. Jiang, Ph.D. Patent Examiner, AU 1617 May 13, 2002

RUSSELL TRAVERS
PRIMARY EXAMINER
GROUP 1200